United Therapeutics Corporation
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
About
CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Employees
1,168
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNGS
Address
1000 Spring Street, Silver Spring, MD 20910, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 28, 2025 | — | — | — | — |
| Jul 29, 2025 | — | — | — | — |
| Apr 29, 2025 | — | — | — | — |
| Feb 19, 2025 | 6.54 | — | — | — |
| Oct 30, 2024 | 6.42 | 6.39 | -0.03 | -0.47% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 6 | — | 14 |
| Average estimate | — | 6.73 | — | 27.74 |
| Low estimate | — | 5.97 | — | 22.80 |
| High estimate | — | 7.24 | — | 30.11 |
| Last year EPS | — | 6.17 | — | 24.58 |
[stock_revenue_estimate]
Growth estimates
Current qtr
60.900%
Next qtr. (Mar 2025)
16.540%
Current year
34.060%
Next year (Dec 2025)
11.360%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 2.33B | 1.94B | 1.69B | 1.48B | 1.45B |
| Cost of revenue | 257.50M | 151.60M | 122.50M | 108.10M | 117.60M |
| Gross profit | 2.07B | 1.78B | 1.56B | 1.38B | 1.33B |
| Operating expense | |||||
| Research & development | 408.00M | 322.90M | 540.10M | 357.70M | 1.18B |
| Selling general and admin | 477.10M | 482.10M | 467.00M | 423.90M | 336.20M |
| Other operating expenses | — | — | — | — | — |
| Operating income | 1.18B | 979.70M | 555.90M | 593.60M | -187.60M |
| Non operating interest income | |||||
| Income | 162.70M | 45.20M | 16.70M | 28.60M | 44.20M |
| Expense | 59.30M | 32.40M | 18.60M | 23.50M | 44.20M |
| Other income expense | -14.00M | -41.90M | 39.90M | 40.20M | 22.60M |
| Pretax income | 1.27B | 950.60M | 593.90M | 638.90M | -165.00M |
| Tax provision | 289.50M | 223.30M | 118.10M | 124.10M | -60.50M |
| Net income | 984.80M | 727.30M | 475.80M | 514.80M | -104.50M |
| Basic EPS | 21.04 | 15.98 | 10.60 | 11.65 | -2.39 |
| Diluted EPS | 19.81 | 15.00 | 10.06 | 11.54 | -2.39 |
| Basic average shares | 46.80M | 45.50M | 44.90M | 44.20M | 43.80M |
| Diluted average shares | 46.80M | 45.50M | 44.90M | 44.20M | 43.80M |
| EBITDA | 1.39B | 1.04B | 664.70M | 721.40M | -74.90M |
| Net income from continuing op. | 984.80M | 727.30M | 475.80M | 514.80M | -104.50M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 7.17B | 6.04B | 5.17B | 4.62B | 3.91B |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 1.21B | 961.20M | 894.80M | 738.70M | 738.40M |
| Other short term investments | 1.79B | 1.88B | 1.04B | 1.10B | 747.50M |
| Accounts receivable | 278.90M | 220.40M | 198.70M | 157.40M | 151.40M |
| Other receivables | — | — | — | — | — |
| Inventory | 111.80M | 102.00M | 93.80M | 86.50M | 93.40M |
| Prepaid assets | — | — | — | — | — |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 166.20M | 219.20M | 100.40M | 88.30M | 133.80M |
| Non current assets | |||||
| Properties | — | — | — | — | — |
| Land and improvements | 148.00M | 142.70M | 132.60M | 74.90M | 74.40M |
| Machinery furniture equipment | 381.20M | 353.90M | 322.90M | 325.00M | 318.20M |
| Construction in progress | 259.10M | 110.90M | 55.10M | 47.40M | 42.00M |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -428.20M | -382.70M | -342.40M | -309.30M | -269.40M |
| Goodwill | 147.90M | 72.50M | 72.60M | 186.10M | 186.30M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 80.50M | 16.50M | 16.60M | 130.10M | 130.30M |
| Investments and advances | 1.91B | 1.32B | 1.65B | 1.15B | 767.50M |
| Other non current assets | 546.60M | 442.00M | 370.10M | 408.50M | 384.60M |
| Total liabilities | 1.18B | 1.25B | 1.21B | 1.22B | 1.13B |
| Current liabilities | |||||
| Accounts payable | 5.60M | 4.10M | 3.80M | 4.10M | 9.90M |
| Accrued expenses | 292.40M | 225.80M | 170.80M | 182.90M | 138.50M |
| Short term debt | 400.00M | — | — | — | 250.00M |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | 35.40M | 80.80M | 102.40M | 96.80M | 25.00M |
| Other current liabilities | 71.00M | 32.50M | 28.40M | 39.50M | 39.60M |
| Non current liabilities | |||||
| Long term debt | 300.00M | 800.00M | 800.00M | 800.00M | 600.00M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 77.80M | 104.60M | 104.80M | 96.50M | 70.00M |
| Shareholders equity | |||||
| Common stock | 700,000 | 700,000 | 700,000 | 700,000 | 700,000 |
| Retained earnings | 6.03B | 5.04B | 4.32B | 3.84B | 3.33B |
| Other shareholders equity | -12.80M | -55.50M | -23.00M | -14.20M | -14.20M |
| Total shareholders equity | 5.98B | 4.80B | 3.96B | 3.40B | 2.78B |
| Additional paid in capital | 2.55B | 2.39B | 2.25B | 2.15B | 2.05B |
| Treasury stock | 2.58B | 2.58B | 2.58B | 2.58B | 2.58B |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||||
| Net Income | 984.80M | 727.30M | 475.80M | 514.80M | -104.50M | 589.20M | 417.90M | 713.70M | 651.60M | 340.10M | 174.56M | 304.44M | 217.87M | 105.92M | 19.46M | -49.33M | 19.86M | 73.97M | 65.02M | 15.45M | -9.97M | -23.65M | -37.29M | -75.61M | -33.50M | -12.80M |
| Depreciation | 53.20M | 51.30M | 49.90M | 49.90M | 45.90M | 35.90M | 31.00M | 31.60M | 32.90M | 32.20M | 31.26M | 27.15M | 20.54M | 17.92M | 11.39M | 4.54M | 3.43M | 1.46M | 2.41M | 2.28M | 2.33M | 3.14M | 3.52M | -79,736 | -1.30M | — |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | 185.11M | 104.34M | 136.23M | 81.43M | 41.92M | -1.04M | -34.39M | -3.28M | -37.05M | -18.13M | — | — | — | — | — | — | — |
| Stock-Based Compensation | 39.10M | 106.80M | 138.50M | 163.80M | 45.40M | -26.40M | 73.50M | 12.10M | 280.30M | 190.10M | 320.79M | 30.12M | -15.72M | 113.94M | 101.02M | 28.70M | 48.70M | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | -4.90M | 52.50M | 65.90M | -47.00M | -29.70M | 1.80M | -19.40M | 9.50M | 7.50M | 24.20M | 15.78M | 25.54M | 59.02M | 16.84M | 4.68M | 2.18M | 1.98M | 15.58M | 1.30M | — | — | — | — | — | 100,000 | — |
| Accounts Receivable | -58.50M | -21.70M | -41.30M | -6.00M | 24.40M | 121.40M | -82.70M | -21.70M | -30.50M | -35.70M | -10.03M | -23.99M | -16.16M | -23.45M | -21.96M | -2.33M | -4.03M | -9.68M | -454,000 | -3.67M | -1.38M | -5.94M | -2.97M | -398,193 | -100,000 | -100,000 |
| Accounts Payable | — | — | — | — | — | — | 66.20M | 600,000 | 16.97M | -6.75M | 7.51M | -37.21M | 16.66M | -2.73M | -3.65M | 18.51M | -1.07M | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -96.40M | -164.00M | -120.40M | 30.50M | -186.40M | 14.00M | -61.90M | -96.30M | -188.60M | -480.08M | -311.56M | -307.16M | -208.91M | -133.32M | -67.37M | -5.10M | -5.41M | 10.84M | -5.63M | 4.59M | -2.38M | -3.52M | -6.21M | -388,760 | 1.70M | — |
| Operating Cash Flow | 917.30M | 752.20M | 568.40M | 706.00M | -204.90M | 735.90M | 424.60M | 649.50M | 770.17M | 249.17M | 332.66M | 155.11M | 154.73M | 137.03M | 42.54M | -37.22M | 60.18M | 55.12M | 44.52M | 18.64M | -11.40M | -29.98M | -42.95M | -76.48M | -33.10M | -12.90M |
| Investing Activities | ||||||||||||||||||||||||||
| Capital Expenditures | -230.40M | -138.80M | -120.80M | -56.90M | -83.70M | -184.40M | -78.00M | -38.00M | -49.80M | -47.40M | -31.91M | -111.91M | -35.98M | -18.64M | -95.40M | -124.42M | -38.66M | -15.63M | -6.12M | -4.40M | -6.67M | -3.58M | -647,000 | -639,875 | -2.30M | -1.00M |
| Net Intangibles | — | — | — | — | — | — | — | -5.20M | 350.00M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | -89.20M | — | — | — | -20.50M | -129.10M | -60.30M | -43.30M | — | — | -30.77M | — | -3.55M | — | -3.57M | — | — | — | — | — | — | — | — | -8.13M | — | — |
| Purchase of Investments | -2.51B | -1.71B | -1.90B | -2.31B | -1.27B | -862.00M | -770.20M | -800,000 | -117.00M | -163.70M | -792.96M | -579.32M | -815.68M | -662.23M | -310.63M | -345.96M | -301.99M | -204.76M | -77.53M | -37.47M | -44.71M | -11.22M | -152.52M | -56.66M | -114.30M | -10.50M |
| Sale of Investments | 2.14B | 1.03B | 1.53B | 1.63B | 1.04B | 400.90M | 72.90M | 130.40M | 320.40M | 549.60M | 529.90M | 527.86M | 733.88M | 457.73M | 249.08M | 297.90M | 318.94M | 118.76M | 12.90M | 30.00M | — | 140.57M | 18.39M | 76.45M | 92.60M | — |
| Investing Cash Flow | -719.60M | -811.50M | -486.90M | -738.50M | -335.40M | -820.60M | -835.50M | 48.30M | 153.60M | 338.50M | -325.74M | -163.36M | -121.33M | -209.24M | -162.62M | -172.48M | -21.71M | -101.63M | -70.74M | -12.87M | -47.54M | 120.36M | -134.78M | 7.16M | -24.10M | -11.50M |
| Financing Activities | ||||||||||||||||||||||||||
| Long-Term Debt Issuance | — | 800.00M | — | — | 800.00M | 250.00M | 250.00M | — | — | 140.00M | — | — | 250.00M | 70.00M | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | -100.00M | -800.00M | — | -50.00M | -200.00M | -250.00M | — | -8.80M | -133.20M | -317.80M | -1.32M | -999,000 | -251.04M | -31.44M | — | -23,000 | -10,000 | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | -2.70M | -7.50M | — | -1.70M | -700,000 | -13.20M | -700,000 | -900,000 | 37.40M | 30.80M | 9.30M | 3.05M | -29.44M | 22.77M | 4.41M | 21.09M | 29.60M | 10.76M | — | — | — | — | — | 159,418 | -200,000 | — |
| Financing Cash Flow | -216.50M | -18.90M | -10.80M | -105.40M | 1.20B | -9.30M | 253.40M | -505.40M | -486.35M | -626.77M | -31.73M | -185.95M | -242.48M | 61.33M | 4.41M | 171.07M | 50.48M | -167.88M | 14.97M | 7.09M | 4.09M | 245,000 | -2.80M | 206.67M | 58.20M | 22.90M |
| Other Cash Details | ||||||||||||||||||||||||||
| End Cash Position | 1.21B | 961.20M | 894.80M | 738.70M | 738.40M | 669.20M | 705.10M | 1.02B | 831.80M | 397.70M | 284.26M | 159.40M | 162.68M | 252.16M | 100.35M | 129.45M | 139.32M | 91.07M | 69.18M | 82.59M | 68.56M | 122.66M | 24.37M | 200.94M | 18.30M | 6.80M |
| Income Tax Paid | 332.50M | 275.70M | 153.30M | 92.80M | 120.20M | 102.70M | 346.90M | 362.40M | 293.30M | 195.60M | 142.14M | 101.51M | 46.51M | 22.68M | 23.93M | 1.63M | 1.56M | — | — | — | — | — | — | — | — | — |
| Interest Paid | 56.00M | 29.10M | 16.20M | 20.70M | 41.00M | 9.40M | 7.50M | 1.50M | 1.00M | 5.50M | 5.52M | 5.30M | 4.10M | 1.82M | 1.25M | 1.25M | 1.21M | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 747.60M | 663.70M | 477.40M | 696.40M | -290.30M | 594.00M | 387.90M | 605.60M | 333.00M | 307.90M | 393.36M | 211.72M | 214.22M | 192.89M | 4.32M | -173.61M | 10.29M | 33.75M | 37.05M | 15.56M | -15.57M | -25.84M | -39.59M | -31.75M | -26.00M | -10.60M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| iShares Core S&P Midcap ETF | Nov 30, 2024 | 1,429,009 | 505.05M | 3.20% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 1,409,533 | 498.17M | 3.16% |
| Vanguard Small-Cap Index Fund | Sep 30, 2024 | 1,113,834 | 393.66M | 2.49% |
| Vanguard Specialized-Health Care Fund | Oct 31, 2024 | 903,467 | 319.31M | 2.02% |
| Vanguard Small Cap Value Index Fund | Sep 30, 2024 | 753,940 | 266.47M | 1.69% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 665,178 | 235.09M | 1.49% |
| Pacer U.S. Cash Cows 100 ETF | Oct 31, 2024 | 545,735 | 192.88M | 1.22% |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | Nov 30, 2024 | 545,113 | 192.66M | 1.22% |
| Capitol Ser Tr-Fuller & Thaler Behavioral Small Cap Equity Fd | Sep 30, 2024 | 535,932 | 189.41M | 1.20% |
| Vanguard/Windsor Fund Inc. | Oct 31, 2024 | 482,270 | 170.45M | 1.08% |
Article
UTHR or ZTS: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
Feb 7, 2025
Article
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Feb 5, 2025
Article
United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced full enrollment of the TETON 1 study evaluating the use of Tyvaso® (treprostinil) inhalation solution (nebulized Tyvaso) for the treatment of idiopathic pulmonary fibrosis (IPF). The TETON 1 study enrolled 598 patients and is part of the three-study global TETON clinical trial program evaluating the use of inhaled treprostinil in IPF and a s.
Feb 4, 2025
